King Pharmaceuticals Research and Development, Inc.

Mojgan Aghazadeh Tabrizi

Pier Giovanni Baraldi

Pier Andrea Borea

Allan R Moorman

Delia Preti

The present invention provides compounds of the formula which are adenosine Areceptor antagonists and, thus, may be employed for the treatment of conditions and diseases mediated by the adenosine Areceptor activity. Such conditions include, but are not limited to, chronic and acute inflammatory diseases involving degranulation of mast cells, e.g., asthma, allergic rhinitis and allergic dermatitis; impaired sensitivity to insulin, e.g., type 2 diabetes, pre-diabetic state, and impaired glucose tolerance; diseases in which angiogenesis is a key component of pathogenesis, e.g., solid tumors and angiogenic retinopathies; apnea of preterm infants; myocardial reperfusion injury; inflammatory bowel disease; autoimmune diseases, such as rheumatoid arthritis, multiple sclerosis, and lupus erythematosis; diseases involving microvascular abnormalities of the retina that are mediated by adenosine Areceptors, e.g., retinopathy of prematurity, macular degeneration, and diabetic retinopathy; and cardiac diseases including hyperplasia consequent to hypertension, arteriosclerosis, and heart attack.

Adenosine A2B receptor antagonists

A class of novel antagonists for the adenosine Areceptor are disclosed. These compounds are useful as therapeutic agents for a number of diseases and medical conditions that are mediated by the Areceptor. The compounds of this invention are also useful as diagnostic agents for the Areceptor.

Growing community of inventors

Ferrara, Italy

Mojgan Aghazadeh Tabrizi